Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,173,700.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $544.60, for a total value of $5,173,700.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,063,379.80. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Price Performance

NASDAQ UTHR opened at $531.79 on Thursday. The stock has a market capitalization of $22.57 billion, a P/E ratio of 19.63, a P/E/G ratio of 1.76 and a beta of 0.58. The business has a 50 day simple moving average of $553.77 and a 200 day simple moving average of $529.94. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the business posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on UTHR. Royal Bank Of Canada lifted their price target on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $644.82.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter worth $31,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.